Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - néoplasmes du sein - agents antinéoplasiques - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Union européenne - français - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leucémie, myéloïde, aiguë - agents antinéoplasiques - vyxeos liposomale est indiqué pour le traitement des adultes ayant récemment reçu un diagnostic, la thérapie liée à la leucémie myéloïde aiguë (aml-t) ou de lam avec myélodysplasie changements liés à l' (aml-mrc).

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - pertuzumabum, trastuzumabum - solution injectable - pertuzumabum 600 mg, trastuzumabum 600 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, saccharum, polysorbatum 20, dl-methioninum, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - le cancer du sein - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - pertuzumabum, trastuzumabum - solution injectable - pertuzumabum 1200 mg, trastuzumabum 600 mg, hyaluronidasum humanum adnr, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, saccharum, polysorbatum 20, dl-methioninum, aqua ad iniectabile q.s. ad solutionem pro 15 ml. - le cancer du sein - biotechnologika

Canada - français - Health Canada

jazz pharmaceuticals ireland limited - daunorubicine; cytarabine - poudre - 44mg; 100mg - daunorubicine 44mg; cytarabine 100mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jazz pharmaceuticals switzerland gmbh - cytarabinum, daunorubicinum - poudre pour solution à diluer une perfusion - cytarabinum 100 mg, daunorubicinum 44 mg, distearoylphosphatidylcholinum, distearoylphosphatidylglycerolum natricum, cholesterolum, cupri(ii) d-gluconas, trolaminum, saccharum, pro vitro. - vyxeos liposomal ist indiziert zur behandlung von erwachsenen mit neu diagnostizierter, therapieassoziierter akuter myeloischer leukämie (t-aml) oder aml mit myelodysplasie-assoziierten veränderungen (aml-mrc). - synthetika

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - mélanome - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - relatlimabum, nivolumabum - solution à diluer pour perfusion - relatlimabum 80 mg, nivolumabum 240 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, acidum penteticum, aqua ad iniectabile ad solutionem pro 20 ml. - fortgeschrittenes melanom - biotechnologika

Canada - français - Health Canada

hoffmann-la roche limited - trastuzumab; pertuzumab - solution - 40mg; 80mg - trastuzumab 40mg; pertuzumab 80mg - antineoplastic agents

Canada - français - Health Canada

hoffmann-la roche limited - trastuzumab; pertuzumab - solution - 60mg; 60mg - trastuzumab 60mg; pertuzumab 60mg - antineoplastic agents